Target intelligence / Profile preview

Cyclin N-terminal domain-containing protein 1 (CNTD1)

Target
CNTD1
Molecular classification
Other (cyclin-like/regulator of meiotic recombination)
01

Overview

Cyclin N-terminal domain-containing protein 1 (CNTD1) is a cyclin-like protein primarily involved in coordinating meiotic crossover formation and cell-cycle progression in germ cells, notably in mammals. CNTD1 is a regulator of meiotic recombination required for the differentiation and maturation of crossover-specific recombination complexes during meiosis. CNTD1 acts in a complex with PRR19 and is essential for the repair of programmed DNA double-strand breaks. Unlike canonical cyclins, mouse CNTD1 exists in a shortened form that does not bind cyclin-dependent kinases but instead interacts with the Replication Factor C (RFC) complex and the SKP1-Cullin-Fbox (SCF) complex, influencing both crossover formation (by regulating MLH1-MLH3 function) and cell cycle control (by facilitating degradation of WEE1 kinase to allow cell-cycle progression). The protein plays a "stop-go" regulatory role during meiotic prophase I, ensuring chromosomal crossovers are completed before metaphase progression and the first meiotic division proceed. Loss of CNTD1 function impairs crossover differentiation and delays DSB repair, leading to reproductive defects such as infertility. CNTD1 is not a classical cyclin: it lacks a canonical cyclin box domain and does not bind cyclin-dependent kinases in vivo. It is not targeted by drugs and has no current use as a clinical biomarker or therapeutic target.

Other names
Cyclin N-terminal domain-containing protein 1CNTD1CNTDFLJ40137COSA1
02

Biological functions

Meiotic recombination (crossover formation)Regulation of cell cycle progression (especially during meiotic prophase I)Coordination of DNA double-strand break (DSB) repair
03

Disease associations

Other (Defects in CNTD1 disrupt meiotic crossing over, which may cause infertility; however, no direct links to common human disease categories such as cancer, inflammation, or neurodegeneration are established)

Beyond the preview

Go deeper on Cyclin N-terminal domain-containing protein 1 (CNTD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin N-terminal domain-containing protein 1 (CNTD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call